VIR-576 (original) (raw)

VIR-576 is an experimental drug that is under clinical trials for the treatment of HIV-1 infections. VIR-576 is synthetic peptide that binds to HIV-1's hydrophobic fusion peptide gp41, preventing the virus from inserting itself into a host cell's membrane to initiate an infection. This drug is a synthesized variant of a highly specific natural entry inhibitor designated as (virus-inhibitory peptide). The design of VIR-576 was based on VIRIP which in turn was discovered in 2007 by and coworkers. This product is being developed by VIRO Pharmaceuticals GmbH & Co. KG.